Medication Use and Clinical Outcomes by the Dutch Institute for Clinical Auditing Medicines Program: Quantitative Analysis

Rawa Kamaran Ismail   ^{1 *} , PhD, PharmD ;   Jesper van Breeschoten   ^{2 *} , PharmD ;   Silvia van der Flier   ³ , PhD ;   Caspar van Loosen   ⁴ , MSc ;   Anna Maria Gerdina Pasmooij   ⁵ , PhD ;   Maaike van Dartel   ⁵ , PhD ;   Alfons van den Eertwegh   ⁶ , PhD, MD ;   Anthonius de Boer   ¹ , MD, PhD ;   Michel Wouters   ⁷ , MD, PhD ;   Doranne Hilarius   ⁸ , PhD, PharmD

¹ Division of Pharmacoepidemiology and Clinical Pharmacology, University of Utrecht, Utrecht, The Netherlands

² Dutch Institute for Clinical Auditing, Leiden, The Netherlands

³ Stichting Volksgezondheidszorg (VGZ), Arnhem, The Netherlands

⁴ Dutch Association of Hospital Pharmacists, De Meern, The Netherlands

⁵ Medicines Evaluation Board, Utrecht, The Netherlands

⁶ Department of Medical Oncology, Amsterdam University Medical Center, location VUmc, Amsterdam, The Netherlands

⁷ Department of Biomedical Data Sciences, Leiden University Medical Centre, Leiden, The Netherlands

⁸ Rode Kruis Ziekenhuis, Beverwijk, The Netherlands

*these authors contributed equally